Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality
Pranay Sinha, Benjamin P. Linas
Abstract
Recent randomized trials suggest that interleukin-6 inhibitors reduce mortality due to severe coronavirus disease 2019. Using a decision tree model, we found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16 520 per quality-adjusted life year gained (95% credible interval, 10 760-51 530).
Topics & Concepts
MedicineTocilizumabDexamethasoneCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseCoronavirusInternal medicineVirologyIntensive care medicineInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research